US Patent No: 6,677,155

Number of patents in Portfolio can not be more than 2000

Triple hybrid amplicon vector systems to generate retroviral packaging lines

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a triple hybrid vector amplicon system comprising genetic elements derived from Herpes Simplex Virus (HSV), Epstein-Barr Virus (EBV) or Adeno-Associated Virus (AAV), and a retrovirus. The vector was developed to stably transform cells, both in culture or in vivo, into retrovirus packaging cells in a single step. This step can be accomplished both by transfection using liposomes, electroporation, calcium phosphate, or any other methodology used to transfer naked or complexed DNA into cells or by infection when the vector is packaged as an amplicon vector in HSV virions.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE GENERAL HOSPITAL CORPORATIONBOSTON, MA, US1443

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Breakefield, Xandra O Newton Center, MA 41 214
Saeki, Yoshinaga Arlington, MA 7 14
Sena-Esteves, Miguel Philadelphia, PA 2 2

Cited Art Landscape

Patent Info (Count) # Cites Year
 
ATI MANUFACTURING LTD. (1)
5,741,486 Safe vectors for gene therapy 33 1995
 
BAYLOR COLLEGE OF MEDICINE (1)
5,631,236 Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk 85 1993
 
GENZYME CORPORATION (1)
5,670,488 Adenovirus vector for gene therapy 114 1993
 
Human Gene Therapy Research Institute (1)
5,830,727 Herpes simplex virus amplicon mini-vector gene transfer system 20 1995
 
OXFORD BIOMEDICA (UK) LIMITED (1)
5,691,177 Recombinant retroviruses expressing a protein that converts a pro-drug into a cytotoxic agent 44 1995
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
5,830,725 Rapid, stable high-titre production of recombing retrovirus 27 1995
 
THE GENERAL HOSPITAL CORPORATION (1)
5,688,773 Method of selectively destroying neoplastic cells 25 1994
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
5,529,774 In vivo transfer of the HSV-TK gene implanted retroviral producer cells 46 1991
 
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (1)
5,756,283 Method for improved production of recombinant adeno-associated viruses for gene therapy 51 1995
 
THE UNIVERSITY OF BRITISH COLUMBIA (1)
5,763,217 Method of using, process of preparing and composition comprising recombinant herpesvirus vectors 18 1995
 
THOMAS JEFFERSON UNIVERSITY (1)
5,763,242 Method for increasing transduction efficiency of recombinant retroviral vectors 5 1995
 
UNIVERSITY OF ROCHESTER (1)
5,601,818 Cancer therapy utilizing malignant cells expressing HSV-TK 23 1994

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
INSTITUT NATIONAL DE RECHERCHE SCIENTIFIQUE (1)
7,598,071 Infectious clone of human parvovirus B19 and methods 0 2004
 
Institut National de Rechesche Scientifique (1)
8,603,784 Infectious clone of human parvovirus B19 and methods 0 2009

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 13, 2015
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00